The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

Changes in microbiome predict risk for sexually transmitted disease
Infectious Disease & AMR

Changes in microbiome predict risk for sexually transmitted disease

JAN 22, 2025
Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round
Finance

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round

JAN 15, 2025
Penn Medicine launches a pioneering project to study the human virome puzzle
Animal Health

Penn Medicine launches a pioneering project to study the human virome puzzle

JAN 14, 2025
MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study
Clinical & Manufacturing

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study

JAN 8, 2025
A new way to determine whether a species will successfully invade an ecosystem
Pharma & Human Health

A new way to determine whether a species will successfully invade an ecosystem

JAN 7, 2025
Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics
Biotics and Supplements

Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics

DEC 17, 2024
Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer
Clinical & Manufacturing

Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer

DEC 17, 2024
Possible colon cancer vaccine target uncovered in bacteria
Gastrointestinal

Possible colon cancer vaccine target uncovered in bacteria

DEC 12, 2024
SNIPR Biome receives up to €20 million European backing to advance therapies AMR
Finance

SNIPR Biome receives up to €20 million European backing to advance therapies AMR

DEC 10, 2024
UCalgary startup Taylored Biotherapeutics to commercialize psychobiotic therapies
Finance

UCalgary startup Taylored Biotherapeutics to commercialize psychobiotic therapies

DEC 2, 2024
A new simple and effective tool that recommends the best possible phage cocktail for a given patient
Infectious Disease & AMR

A new simple and effective tool that recommends the best possible phage cocktail for a given patient

NOV 28, 2024